SAR study of 1,2-benzisothiazole dioxide compounds that agonize HIF-2 stabilization and EPO production

Bioorg Med Chem. 2023 Jan 1:77:117041. doi: 10.1016/j.bmc.2022.117041. Epub 2022 Oct 3.

Abstract

Benzisothiazole dioxide compound was reported to agonize HIF-2 stabilization and improve EPO production, thus conceiving a potential strategy to treat disease with chronic hypoxia exemplified by renal anemia. Herein, on the bases of multiple molecular and cellular assays, a series of benzisothiazole derivatives have been synthesized and their structure-activity relationship was evaluated. The SAR and molecular docking studies have revealed the structural insights on the rational design of HIF-2 agonist and discovered a more potential 5-bromine substituted analogue, which showed 2-4 times improvement of HIF-2 downstream gene transcriptions, including EPO production. The present results suggest the therapeutic potential of the compounds for diseases related to EPO insufficiency.

Keywords: Agonist; Benzisothiazole; EPO; HIF-2; SAR.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Anemia* / drug therapy
  • Basic Helix-Loop-Helix Transcription Factors
  • Erythropoietin* / genetics
  • Erythropoietin* / pharmacology
  • Humans
  • Molecular Docking Simulation

Substances

  • Erythropoietin
  • benzisothiazole
  • Basic Helix-Loop-Helix Transcription Factors